Private company

Sigilon Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address100 Binney Street, Ste 600, Cambridge, Ma 02142²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-337.3%Operating margin³

-336.8%Net margin⁴

34.8%Revenue growth, 2022³

-111.4%Return on equity³

0.31×Debt to equity³

-$52.0MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and development

Research and development94¢$37.6M
Interest6¢$2.3M

Out of $12.9M in revenue.³⁴ The company lost money this year.

Financial statements

Revenue⁵³$12.9M in 2022−3% since 2020

Operating income⁵³-$43.7M in 2022−17% since 2020

Net income⁵³⁴-$43.6M in 2022−20% since 2020

Fiscal year	2020	2021	2022
Revenue	$13.4M⁵	$9.6M³	$12.9M³
Research and development	$53.5M⁵	$65.1M³	$37.6M³
Operating income	-$52.6M⁵	-$75.6M³	-$43.7M³
Interest	$1.2M⁵	$2.0M³	$2.3M³
Income tax	$0⁵	$0³	$0³
Net income	-$54.6M⁵	-$77.3M³	-$43.6M⁴
Earnings per share	-$7.55⁵	-$2.43³	-$1.34³
Earnings per share (diluted)	-$7.55⁵	-$2.43³	-$1.34³

Total assets⁵³$87.3M in 2022−61% since 2020

Total liabilities⁵³$48.1M in 2022−39% since 2020

Shareholders’ equity⁵³$39.1M in 2022

Cash⁵³$42.1M in 2022−45% since 2019

Long-term debt⁵³$12.0M in 2022−39% since 2020

Fiscal year	2019	2020	2021	2022
Cash	$76.6M⁵	$202.2M⁵	$107.1M³	$42.1M³
Current assets		$204.2M⁵	$126.4M³	$74.4M³
Total assets		$225.1M⁵	$144.4M³	$87.3M³
Current liabilities		$47.0M⁵	$34.9M³	$31.0M³
Long-term debt		$19.8M⁵	$18.4M³	$12.0M³
Total liabilities		$78.9M⁵	$67.2M³	$48.1M³
Shareholders’ equity	-$77.8M⁵	$146.2M³	$77.2M³	$39.1M³
Shares outstanding		31.5M shares⁵	32.4M shares³	32.5M shares³

Cash from operations⁵³-$51.5M in 2022−17% since 2020

Capital spending⁵³$537.0K in 2022−45% since 2020

Free cash flow⁵³-$52.0M in 2022−17% since 2020

Fiscal year	2020	2021	2022
Cash from operations	-$61.6M⁵	-$78.4M³	-$51.5M³
Capital spending	$972.0K⁵	$1.8M³	$537.0K³
Free cash flow	-$62.6M	-$80.2M	-$52.0M
Dividend per share	$0.00⁵	$0.00³	$0.00³

Compare Sigilon Therapeutics, Inc. with another company

Leadership

Who has led Sigilon Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Coelho Rogerio Vivaldi2020–2023

President

Coelho Rogerio Vivaldi2020–2023

Chief financial officer

Chief operating officer

Devyn Smith2020–2021

2025

Chief executive officerCoelho Rogerio Vivaldi Dec 3, 2020 to Aug 11, 2023⁷
PresidentCoelho Rogerio Vivaldi Dec 3, 2020 to Aug 11, 2023⁷
Chief financial officerJosias Pontes Feb 22, 2022 to Aug 11, 2023⁸
Chief financial officerGlenn Reicin Dec 3, 2020 to Feb 16, 2021⁹
Chief operating officerDevyn Smith Dec 3, 2020 to Feb 16, 2021¹⁰

Board members and other officers (13)

CTOOQing Sarah Yuan Mar 10, 2022 to Aug 11, 2023¹¹
Chief Scientific OfficerPhilip Ashton-Rickardt Jun 14, 2021 to Aug 11, 2023¹²
VP, Head of FinanceJosias Pontes Jun 21, 2021 to Jan 4, 2022¹³
CHIEF MEDICAL OFFICERMay Orfali Dec 1, 2021 to Feb 22, 2022¹⁴
Chief Medical OfficerDeya Corzo Dec 3, 2020 to Feb 16, 2021¹⁵
Board memberBrooke Story Jun 16, 2021 to May 27, 2022¹⁶
Board memberCoelho Rogerio Vivaldi Dec 3, 2020 to Aug 11, 2023⁷
Board memberDouglas G. Cole Dec 3, 2020 to Aug 11, 2023¹⁷
Board memberEric D. Shaff Dec 3, 2020 to Aug 11, 2023¹⁸
Board memberKavita Patel Dec 3, 2020 to Aug 11, 2023¹⁹
Board memberRobert R. Ruffolo Dec 3, 2020 to Aug 11, 2023²⁰
Board memberStephen N. Oesterle Dec 3, 2020 to Aug 11, 2023²¹
General counselMatthew Paul Kowalsky Mar 1, 2023 to Aug 11, 2023²²

Timeline

Dec 3, 2020New chief executive Coelho Rogerio Vivaldi becomes CEO⁷

Filings

101 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 21 major events, 48 insider forms, 1 large holders, 23 other. The latest 20:

Feb 14, 2024SC 13G/A EDGAR
Aug 21, 202315-12G EDGAR
Aug 15, 2023EFFECT EDGAR
Aug 15, 20234 FORM 4 SUBMISSION EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 20234 EDGAR
Aug 11, 2023S-8 POS EDGAR
Aug 11, 2023S-8 POS EDGAR
Aug 11, 2023S-8 POS EDGAR
Aug 11, 2023S-8 POS EDGAR
Aug 11, 2023POS AM EDGAR

The 101 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 1 such filings since October 2021:

Feb 14, 2024SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSigilon Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARSigilon Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARSigilon Therapeutics, Inc. 10-K for fiscal 2022
4
SEC EDGARSigilon Therapeutics, Inc. 10-K for fiscal 2022
5
SEC EDGARSigilon Therapeutics, Inc. 10-K for fiscal 2020
6
SEC EDGARSigilon Therapeutics, Inc. 10-Q for fiscal 2023
7
SEC EDGARCoelho Rogerio Vivaldi, Chief executive officer
8
SEC EDGARJosias Pontes, Chief financial officer
9
SEC EDGARGlenn Reicin, Chief financial officer
10
SEC EDGARDevyn Smith, Chief operating officer
11
SEC EDGARQing Sarah Yuan, CTOO
12
SEC EDGARPhilip Ashton-Rickardt, Chief Scientific Officer
13
SEC EDGARJosias Pontes, VP, Head of Finance
14
SEC EDGARMay Orfali, CHIEF MEDICAL OFFICER
15
SEC EDGARDeya Corzo, Chief Medical Officer
16
SEC EDGARBrooke Story, Board member
17
SEC EDGARDouglas G. Cole, Board member
18
SEC EDGAREric D. Shaff, Board member
19
SEC EDGARKavita Patel, Board member
20
SEC EDGARRobert R. Ruffolo, Board member
21
SEC EDGARStephen N. Oesterle, Board member
22
SEC EDGARMatthew Paul Kowalsky, General counsel